ColBar Life Science Ltd. (“ColBar”) is a biomaterials company specializing in aesthetics and reconstructive medicine. ColBar's novel products are based on its patented
GLYMATRIX™ technology, which delivers the well recognized benefits of collagen-based biomaterials, while also providing safe and long lasting products. ColBar's's GLYMATRIX™technology is based on a natural biochemical process called glycation. This process uses sugars to cross-link collagen molecules producing a collagen matrix that can be tailored to deliver range of products of varying physical properties and, importantly, customized longevity.

EVOLENCE^® ColBar's dermal filler that restores shape to facial wrinkles sets a new standard in biodegradable dermal filler technology.

Patient sensitivity testing is not a prerequisite in advance of EVOLENCE^® administration.

EVOLENCE^® has obtained CE Mark on October 2004 and currently approved/licensed for sales in Europe, Canada, South Korea and Israel.

ColBar has applied for FDA's Premarket Approval in the United States. Currently EVOLENCE^® is unapproved for sales in the USA.

ColBar plans to extend the EVOLENCE^® product line to four products that will provide physicians and health professional users with flexibility in treating fine lines and wrinkles, adding fullness to lips, shaping facial contours, and correcting deep facial folds. The first of these line extensions, EVOLENCE^® Breeze, recommended for upper to mid dermis wrinkle correction has obtained CE mark and currently approved/licensed for sales and marketing in Europe, Israel, Canada and South Korea.

ColBar's second commercial product, OSSIX^® PLUS, a porcine collagen membrane used for Guided Bone Regeneration (GBR) and Guided Tissue Regeneration (GTR) to support the formation of new alveolar bone in the oral cavity, has been cleared for sale in the U.S. by the FDA in 2006. OSSIX^® PLUS also holds a CE Mark and is approved for sale in Israel. OSSIX^® PLUS was successfully launched by OraPharma, Inc. in April 2007.